Ernexa Therapeutics (NASDAQ:ERNA) Posts Quarterly Earnings Results, Misses Estimates By $0.10 EPS

Ernexa Therapeutics (NASDAQ:ERNA) posted its quarterly earnings results on Thursday. The company reported ($3.40) EPS for the quarter, missing analysts’ consensus estimates of ($3.30) by ($0.10), FiscalAI reports.

Ernexa Therapeutics Stock Down 3.4%

ERNA traded down $0.15 during trading on Friday, hitting $4.21. The company’s stock had a trading volume of 25,279 shares, compared to its average volume of 1,388,595. The business’s 50 day simple moving average is $5.88 and its 200-day simple moving average is $8.85. The firm has a market cap of $4.93 million, a PE ratio of -0.16 and a beta of 2.57. Ernexa Therapeutics has a one year low of $3.18 and a one year high of $71.50.

Wall Street Analyst Weigh In

A number of analysts have commented on the company. Brookline Capital Markets began coverage on Ernexa Therapeutics in a report on Thursday, May 7th. They issued a “buy” rating and a $30.00 target price for the company. Wall Street Zen downgraded shares of Ernexa Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday. Weiss Ratings reiterated a “sell (e+)” rating on shares of Ernexa Therapeutics in a research note on Friday, July 17th. Finally, Zacks Research raised shares of Ernexa Therapeutics to a “hold” rating in a report on Monday, May 11th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Ernexa Therapeutics presently has an average rating of “Hold” and a consensus price target of $30.00.

Institutional Trading of Ernexa Therapeutics

An institutional investor recently bought a new position in Ernexa Therapeutics stock. Susquehanna International Group LLP acquired a new position in Ernexa Therapeutics Inc. (NASDAQ:ERNA) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 30,854 shares of the company’s stock, valued at approximately $34,000. Susquehanna International Group LLP owned 0.39% of Ernexa Therapeutics as of its most recent SEC filing. 70.55% of the stock is owned by hedge funds and other institutional investors.

About Ernexa Therapeutics

Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc was founded in 2018 and is based in Cambridge, Massachusetts.